SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    E.L. Ong, Raph Goldacre, Michael Goldacre, Differential risks of cancer types in people with Parkinson’s disease: A national record-linkage study, European Journal of Cancer, 2014, 50, 14, 2456

    CrossRef

  2. 2
    Ian Martin, Jungwoo Wren Kim, Valina L. Dawson, Ted M. Dawson, LRRK2 pathobiology in Parkinson's disease, Journal of Neurochemistry, 2014, 131, 5
  3. 3
    Roberta Allegra, Sara Tunesi, Roberto Cilia, Gianni Pezzoli, Stefano Goldwurm, LRRK2-G2019S mutation is not associated with an increased cancer risk: A kin-cohort study, Movement Disorders, 2014, 29, 10
  4. 4
    S. N. Pchelina, A. K. Emelyanov, T. S. Usenko, Molecular basis of Parkinsons’s disease linked to LRRK2 mutations, Molecular Biology, 2014, 48, 1, 1

    CrossRef

  5. 5
    Xiao Li, Wen Zhang, Chen Zhang, Wei Gong, Jinsong Tang, Zhenghui Yi, Dong Wang, Weihong Lu, Yiru Fang, Xiaogang Chen, Yong-Gang Yao, No association between genetic variants of the LRRK2 gene and schizophrenia in Han Chinese, Neuroscience Letters, 2014, 566, 210

    CrossRef

  6. 6
    Javier Ruiz-Martínez, Patricia de la Riva, Maria C. Rodríguez-Oroz, Elisabet Mondragón Rezola, Alberto Bergareche, Ana Gorostidi, Belen Gago, Ainara Estanga, Nerea Larrañaga, Cristina Sarasqueta, Adolfo López de Munain, José F. Martí Massó, Prevalence of cancer in Parkinson's disease related to R1441G and G2019S mutations in LRRK2, Movement Disorders, 2014, 29, 6
  7. 7
    Steven Lubbe, Huw R. Morris, Recent advances in Parkinson’s disease genetics, Journal of Neurology, 2014, 261, 2, 259

    CrossRef

  8. 8
    H. Mortiboys, A. Cox, I. W. Brock, O. Bandmann, The common PARK8 mutation LRRK2 G2019S is not a risk factor for breast cancer in the absence of Parkinson’s disease, Journal of Neurology, 2013, 260, 8, 2177

    CrossRef

  9. 9
    Iakov N Rudenko, Ruth Chia, Mark R Cookson, Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease?, BMC Medicine, 2012, 10, 1, 20

    CrossRef

  10. 10
    D. C. Berwick, K. Harvey, LRRK2 functions as a Wnt signaling scaffold, bridging cytosolic proteins and membrane-localized LRP6, Human Molecular Genetics, 2012, 21, 22, 4966

    CrossRef

  11. 11
    B. D. Looyenga, K. A. Furge, K. J. Dykema, J. Koeman, P. J. Swiatek, T. J. Giordano, A. B. West, J. H. Resau, B. T. Teh, J. P. MacKeigan, Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas, Proceedings of the National Academy of Sciences, 2011, 108, 4, 1439

    CrossRef

  12. 12
    Zhenyu Yue, M. Lenard Lachenmayer, Genetic LRRK2 models of Parkinson's disease: Dissecting the pathogenic pathway and exploring clinical applications, Movement Disorders, 2011, 26, 8